Full Press Release Details
two year results for aflibercept 8 mg from pivotal photon trial demonstrate durable vision gains at extended dosing intervals in diabetic macular edema.
REGN
two year results for aflibercept 8 mg from pivotal photon trial demonstrate durable vision gains at extended dosing intervals in diabetic macular edema
Key Takeaway: two year results for aflibercept 8 mg from pivotal photon trial demonstrate durable vision gains at extended dosing intervals in diabetic macular edema